2012
Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies
Mehnert JM, Kluger HM. Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies. Current Oncology Reports 2012, 14: 449-457. PMID: 22723080, PMCID: PMC4447200, DOI: 10.1007/s11912-012-0249-5.Peer-Reviewed Original ResearchConceptsDriver mutationsSpecific patient subsetsPotential therapeutic strategyPatient subsetsSomatic driver mutationsMetastatic melanomaBedside studiesUveal melanomaTherapeutic strategiesBRAFV600E mutationMalignant transformationMelanomaMolecular classificationDevelopment of inhibitorsHuman samplesMutationsMolecular biologyBRAFDisease
2010
A phase 2 trial of dasatinib in advanced melanoma
Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M. A phase 2 trial of dasatinib in advanced melanoma. Cancer 2010, 117: 2202-2208. PMID: 21523734, PMCID: PMC3116034, DOI: 10.1002/cncr.25766.Peer-Reviewed Original ResearchConceptsProgression-free survivalC-kit mutationsPhase 2 trialResponse ratePartial responseMedian progression-free survivalMelanoma cell proliferationDaily dasatinibMucosal primaryPFS ratesStarting dosageCommon toxicitiesUnresectable melanomaAdvanced melanomaPleural effusionMelanoma patientsPredictive biomarkersMinor responseCombination trialsTumor assessmentDose reductionPatientsPrespecified endpointsDasatinibMelanoma